Cannabis Investing Network

In this episode we are joined by the leading cannabis analyst Alan Brochstein. Alan is known for being the sheriff of the wild west of cannabis and applying his deep analytical insights in the cannabis industry. 

He is founder of New Cannabis Ventures and shares his insights as "the maven" of 420investor. Alan regularly helps us form our opinions on the cannabis space and helps investors make better investment decisions. 

He joins us today in a broad ranging discussion about investor psychology, cannabis fundamentals, company specific discussions and much more. Thanks to Alan for joining us as always.

Twitter - https://twitter.com/Invest420

In this episode we unpack last week's interview with Boris Jordan and review in-depth some of the interesting points he raised. 

We also do a deeper dive into the Trulieve - Harvest merger and share our thoughts on why it's a true value play and what Kim may be hoping to achieve post-integration.

In this jam-packed episode Boris Jordan joins us in an extremely candid conversation about Curaleaf Holdings. Boris is founder and Executive Chairman of Curaleaf Holdings and is one of the industry's most recognized faces. He is also a prolific cannabis investor having invested over $400M of hard cash into Curaleaf and more into other private cannabis opportunities. 

In this wide ranging discussion Boris shares stories and discussions on many topics including:

- The First Inning of Curaleaf: how it all started and where we are now

- Compliance & Custodying: how the recent compliance forced institutional selling is a repeat of 2019

- Guidance: What is driving the massive Q2 growth Curaleaf is projecting?

- Interstate Commerce: why Boris thinks it is inevitable and how they are planning for it

- Driving Down Costs: Technology that could cut manufacturing cost by 90%

- Being National: Why it's important to be in highly competitive markets like California and Oregon

- Wide & Deep: How the recent Trulieve & Harvest merger validates Curaleaf's early thesis

- Florida: what mistakes were made, how they were fixed and the future

- Cost of Capital: refinancing Curaleaf debt in 2022 at 7-8% without warrants

- Private Investing: How Boris fills the "venture investing" role for Curaleaf

- Being the Biggest: Why it matters

- Margins & Growth: How Curaleaf compares to its competition

- M&A: The importance of Select & Grassroots 

- Mistakes: Learning from past issues

Thank you to Boris Jordan for joining us for this episode!

We are joined with a friend of the podcast, Pat Smith, former sell side analyst on Bay St.  

In this episode we cover a broad range of topics including how investors are switching from simply reading headlines to analyzing fundamentals and why cannabis continues to be a value play.  

We discuss how the broader markets are impacting our sector, as well touch on how crypto, gold, bond yields and the vaccine roll out could affect cannabis.

Note: there is an echo in the audio if you listen using headphones; it goes away if you listen through a speaker. Sorry about that, new audio set up this time!

In this episode we talk about watching your back! Cannabis investing is buyer beware and investors should always be thinking about mitigating their downside risk.

We discuss our personal viewpoints, investment philosophies and trading tactics for minimizing your downside risk in cannabis investing 

In this episode we share our thoughts on the market before answering listener questions

- Back to future: how our current pullback is eerily reminiscent of 2019

- Comparisons to crypto, psychedelics and other speculative asset classes

- Legalization let down: why investors shouldn't be discouraged

Listener Questions:

- What do we think about the MSOS ETF? 

- Show new investors be worried if cannabis is regulated similar to alcohol? (see link)

- How do we feel about certain speculative "penny stocks"?

- Questions about cannabis companies exporting to the EU

- Are the Big 5 MSOs the best investments in the sector?

- If we had to start over again, what would our portfolios look like?

Correction: We mentioned 300K patient count in Germany; 300K is the number of prescriptions written; patient count is estimated much lower at 60K

Buckle up boys and girls - in this epic episode we have the one and only CannaVestments (Nick Gastevich) joining us for a deep dive into the big 5 MSOs (now including Verano).

In this episode we discuss

- Overall thoughts on the market and having a long term focus

- Core markets for each of the big 5

- Financial performance for Q4 and 2020

- Where the majority of profits are being generated today

- What excites us for the future of each company

Thanks to Nick for another great and extensive review

Connect with Nick:

Twitter - https://twitter.com/CannaVestments

LinkedIn - https://www.linkedin.com/in/nicholas-gastevich-75841346/

Family Office Website - https://www.vginvests.com/ 

Story time! In this episode we get nostalgic and share our experiences of the ups and downs of cannabis investing from 2017-2019. 

In what was truly the boom and bust of speculative cannabis investing we learned some hard lessons which can be instructive for newer investors.

In this episode:

- Starting with a bang in 2017 with Canopy and Aphria

- Investing in a company at 30c and hitting a 20X return...then watching it come back

- How a private California deal went wrong

- Lessons learned through tough experiences 

In this episode we dive into the psychology behind the sharp pullback our sector has seen and we ask - what are cannabis investors so afraid of?

Agenda:

- Common Retail Mistakes that we see taking place

- The Momentum Trade dying down and what this means

- New York Legalizes! What this means for the industry 

- SAFE and Legalization Talks

- GTI and the Crisis of Confidence

- What we were scared of in the past (and what's changed)

- What are retail investors really afraid of?

Ascend Wellness S1: https://sec.report/Document/0001628280-21-005806/ 

Wall Street Journal Article on Retail Investors Retreating: https://www.wsj.com/articles/individual-investors-retreat-from-markets-after-show-stopping-start-to-2021-11617528781

We are joined by a special guest, Manuj Grover from Aim Gro Consulting.  Manuj has over 20 years of experience in finance and has helped many private Cannabis companies gain access to US and Canadian investors via Regulation A (Reg A) raises, the most recent being Gage Cannabis.

In this episode we cover Reg A raises, one of the many ways for retail investors to participate in pre IPO investments, and how it’s changing the investing landscape as we know it.

The following topics are covered in more detail:

Reg A vs. traditional private placements

Criteria for tier 1 and tier 2 raises

Why Reg A is gaining popularity

Risks and rewards associated with investing in private companies

Dangers associated with Reg A raises

Link: Click here for SEC Form 1 Filings

Companies mentioned: GTII, Gage Cannabis, Juva Life